

LÃ-via Lovato Pires de Lemos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6664612/publications.pdf>

Version: 2024-02-01

12
papers

523
citations

1039406

9
h-index

1281420

11
g-index

12
all docs

12
docs citations

12
times ranked

1008
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Mobile Apps to Support the Care of Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>JMIR MHealth and UHealth</i> , 2017, 5, e4.	1.8	223
2	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. <i>Current Medical Research and Opinion</i> , 2020, 36, 301-327.	0.9	111
3	Fixed dose drug combinations “ are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 1-26.	0.7	47
4	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 279-287.	0.2	32
5	Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0224012.	1.1	29
6	Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 697-709.	1.0	23
7	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. <i>PLoS ONE</i> , 2018, 13, e0199446.	1.1	19
8	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. <i>Pharmacoeconomics</i> , 2018, 36, 161-173.	1.7	17
9	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 991-999.	1.3	15
10	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. <i>PLoS ONE</i> , 2020, 15, e0238476.	1.1	4
11	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 332-342.	0.3	3
12	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. <i>Clinical Diabetes</i> , 0, , .	1.2	0